Related Experiment Video
Updated: May 4, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.2K
CALR frameshift mutation detection in myeloproliferative neoplasms by microfluidic chip analysis.
Michael P Greenwood1, Keith M Newton1, Kristi L Pepper1
1Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, United States.
Laboratory Medicine
|December 25, 2024
Summary
A new microfluidic chip assay accurately detects Calreticulin (CALR) mutations, crucial for diagnosing myeloproliferative neoplasms. This method offers a faster, more streamlined alternative to conventional techniques.
Area of Science:
- Molecular diagnostics
- Hematology
- Genetics
Background:
- Calreticulin (CALR) mutation analysis is vital for diagnosing BCR/ABL1-negative myeloproliferative neoplasms.
- Common CALR mutations (52-bp deletion, 5-bp insertion) represent ~85% of cases.
Purpose of the Study:
- To evaluate a novel microfluidic chip assay for detecting CALR exon 9 mutations.
- To compare the microfluidic assay's performance against conventional diagnostic methods.
Main Methods:
- CALR exon 9 was amplified from various specimen types (blood, bone marrow) using conventional and a new primer pair.
- PCR amplicons were analyzed using a microfluidic chip assay.
- Assay performance was validated against a reference laboratory's conventional method results.
Main Results:
- The microfluidic chip assay demonstrated 100% concordance with the reference method (42/42 samples).
- Both intra-run and inter-run reproducibility were 100%.
- The assay's limit of detection was established at 6% mutant alleles.
Conclusions:
- The microfluidic chip assay for CALR exon 9 mutations is suitable for clinical application.
- This assay offers advantages over conventional methods, including a streamlined workflow, faster results, and a compact instrument size.
